Action 9
Only fund the procurement of drugs and formulations recommended by WHO on the Optimal Formulary List
Committed by:
Donors
Sub-action 9.1

Only fund the procurement of drugs and formulations recommended by WHO on the Optimal Formulary List

PEPFAR, UNITAID

Milestone 9.1.1

Request policy statement from PEPFAR and Global Fund on exclusive funding of Optimal Formulary List

-

Since 2017, PEPFAR has taken  direct action to ensure that PEPFAR funds are not used to purchase ARVs that are no longer standard of care.

 

In its COP18 guidance, PEPFAR highlighted its support for use of preferred, child-friendly formulations:  “For children, PEPFAR supports use of currently preferred regimens (e.g. lopinavir/ritonavir-based first-line regimens for children under 3 years old or 30 kg.) in child-friendly formulations and will support rapid introduction of new drugs and formulations for children (e.g.dolutegravir) as they become available and recommendations are updated. “ [page 56, https://www.pepfar.gov/reports/guidance/c77910.htm ]

PEPFAR funds can no longer be used to purchase nevirapine products for treatment in older children and adults.

Global Fund applies strict rules on optimal procurement. Wambo site only shows optimal drugs and formulations

Document (s)

-

-

-

-

Sub-Actions & Milestones

Updates

Notes

Responsible